684 related articles for article (PubMed ID: 28438043)
1. Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System.
Coons JC; Iasella CJ; Chanas T; Wang N; Williams K; Boyd A; Lyons J; Eckardt J; Rihtarchik L; Merkel A; Chambers A; Lemon LS; Smith R; Ensor CR
Ann Pharmacother; 2017 Aug; 51(8):649-655. PubMed ID: 28438043
[TBL] [Abstract][Full Text] [Related]
2. Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry.
Alexopoulos D; Xanthopoulou I; Deftereos S; Hamilos M; Sitafidis G; Kanakakis I; Pentara I; Vavouranakis M; Davlouros P; Hahalis G; Goudevenos J
J Thromb Haemost; 2016 Jun; 14(6):1146-54. PubMed ID: 26990959
[TBL] [Abstract][Full Text] [Related]
3. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Yudi MB; Clark DJ; Farouque O; Eccleston D; Andrianopoulos N; Duffy SJ; Brennan A; Lefkovits J; Ramchand J; Yip T; Oqueli E; Reid CM; Ajani AE;
Intern Med J; 2016 May; 46(5):559-65. PubMed ID: 26909472
[TBL] [Abstract][Full Text] [Related]
4. Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization.
Kudaravalli M; Althouse AD; Marroquin OC; Khandhar SJ; Sharbaugh MS; Toma C; Conrad Smith AJ; Schindler JT; Lee JS; Mulukutla SR
Int J Cardiol; 2016 Nov; 223():854-859. PubMed ID: 27592042
[TBL] [Abstract][Full Text] [Related]
5. Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention: An Evaluation of Prasugrel or Ticagrelor Versus Clopidogrel.
Verlinden NJ; Coons JC; Iasella CJ; Kane-Gill SL
J Cardiovasc Pharmacol Ther; 2017 Nov; 22(6):546-551. PubMed ID: 28279076
[TBL] [Abstract][Full Text] [Related]
6. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Jackson LR; Peterson ED; McCoy LA; Ju C; Zettler M; Baker BA; Messenger JC; Faries DE; Effron MB; Cohen DJ; Wang TY
J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792656
[TBL] [Abstract][Full Text] [Related]
7. "Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States.
Larmore C; Effron MB; Molife C; DeKoven M; Zhu Y; Lu J; Karkare S; Lieu HD; Lee WC; Vetrovec GW
Catheter Cardiovasc Interv; 2016 Oct; 88(4):535-544. PubMed ID: 26577386
[TBL] [Abstract][Full Text] [Related]
8. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R
JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028
[TBL] [Abstract][Full Text] [Related]
9. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial.
Shahzad A; Khanna V; Kemp I; Shaw M; Mars C; Cooper R; Wilson K; Curzen N; Stables RH
EuroIntervention; 2018 Mar; 13(16):1931-1938. PubMed ID: 29336311
[TBL] [Abstract][Full Text] [Related]
11. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
Westman PC; Lipinski MJ; Torguson R; Waksman R
Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
[TBL] [Abstract][Full Text] [Related]
12. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
[TBL] [Abstract][Full Text] [Related]
13. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet drug selection in PCI to vein grafts in patients with acute coronary syndrome and adverse clinical outcomes: Insights from the British Cardiovascular Intervention Society database.
Sirker A; Kwok CS; Kontopantelis E; Johnson T; Freeman P; de Belder MA; Ludman P; Zaman A; Mamas MA
Catheter Cardiovasc Interv; 2018 Oct; 92(4):659-665. PubMed ID: 29356278
[TBL] [Abstract][Full Text] [Related]
15. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
[TBL] [Abstract][Full Text] [Related]
17. One-Year Clinical Effectiveness Comparison of Prasugrel with Ticagrelor: Results from a Retrospective Observational Study using an Integrated Claims Database.
Effron MB; Nair KV; Molife C; Keller SY; Page RL; Simeone JC; Murphy B; Nordstrom BL; Zhu Y; McCollam PL; Vetrovec GW
Am J Cardiovasc Drugs; 2018 Apr; 18(2):129-141. PubMed ID: 29222628
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Prasugrel and Ticagrelor in Acute Coronary Syndrome. Results of a "Real World" Multicenter Registry.
Almendro-Delia M; García-Alcántara Á; de la Torre-Prados MV; Reina-Toral A; Arboleda-Sánchez JA; Butrón-Calderón M; García-Guerrero A; de la Chica-Ruiz Ruano R; Hidalgo-Urbano R; García-Rubira JC
Rev Esp Cardiol (Engl Ed); 2017 Nov; 70(11):952-959. PubMed ID: 28576388
[TBL] [Abstract][Full Text] [Related]
19. Real-world clopidogrel utilization in acute coronary syndromes: patients selection and outcomes in a single-center experience.
Castini D; Persampieri S; Cazzaniga S; Ferrante G; Centola M; Lucreziotti S; Salerno-Uriarte D; Sponzilli C; Carugo S
Ther Adv Cardiovasc Dis; 2017 Dec; 11(12):323-331. PubMed ID: 29134853
[TBL] [Abstract][Full Text] [Related]
20. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
Clemmensen P; Dridi NP; Holmvang L
Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
